A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy

Table 3

Meta-analytic findings about postoperative macular thickness compared to the baseline.

	No. of studies	Mean difference (95% CI)		I^2 (%)	for heterogeneity
MT after 1 week
IVB for NPDR without DME	—
IVR for NPDR without DME	2 [16, 19]	−11.69 (−19.56, −3.83)	0.004	0	0.80
IVB for NPDR with DME	—
IVR for NPDR with DME	1 [18]	−125.07 (−156.34, −93.80)	0.00001	Not applicable
Total	3 [16, 18, 19]	−45.95 (−91.49, −0.41)	0.05	96	0.00001
MT after 1 month
IVB for NPDR without DME	1 [12]	−90 (−105.11, −74.89)	0.00001	Not applicable
IVR for NPDR without DME	3 [16, 19, 22]	−16.56 (−26.10, −9.02)	0.0001	8	0.34
IVB for NPDR with DME	2 [13, 21]	−84.89 (−147.88, −21.91)	0.008	63	0.10
IVR for NPDR with DME	1 [18]	−153.83 (−212.59, −95.07)	0.00001	Not applicable
Total	9 [11–13, 15, 16, 18, 19, 21, 22]	−49.92 (−78.34, −21.51)	0.0006	93	0.00001
MT after 3 months
IVB for NPDR without DME	—
IVR for NPDR without DME	3 [16, 19, 22]	−25.64 (−32.54, −18.74)	0.00001	3	0.36
IVB for NPDR with DME	3 [13, 14, 21]	−53.55 (−72.29, −34.80)	0.00001	0	0.57
IVR for NPDR with DME	1 [18]	−108.80 (−170.64, −46.96)	0.0006	Not applicable
Total	9 [11, 13–16, 18, 19, 21, 22]	−34.73 (−49.94, −19.51)	0.00001	58	0.01
MT after 6 months
IVB for NPDR without DME	1 [12]	−24.00 (−34.50, −13.50)	0.00001	Not applicable
IVR for NPDR without DME	2 [16, 17]	−24.77 (−43.24, −6.30)	0.009	0	0.88
IVB for NPDR with DME	1 [14]	−109.84 (−174.48, −45.20)	0.0009	Not applicable
IVR for NPDR with DME	2 [18, 20]	−90.25 (−127.24, −53.26)	0.00001	0	0.58
Total	8 [11, 12, 14–18, 20]	−45.22 (−65.37, −25.07)	0.00001	62	0.01

IVB = intravitreal bevacizumab; IVR = intravitreal ranibizumab; NPDR = nonproliferative diabetic retinopathy; MT = macular thickness; DME = diabetic macular edema.